Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Melanoma 24Carcinoma, Renal Cell 15Carcinoma, Non-Small-Cell Lung 15Neoplasm Metastasis 12Urinary Bladder Neoplasms 6Sarcoma 6Prostatic Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Neoplasms 5Kidney Neoplasms 5Ovarian Neoplasms 4Glioblastoma 4Carcinoma, Transitional Cell 4Uveal Melanoma 3Small Cell Lung Carcinoma 3Myelodysplastic Syndromes 3Mesothelioma 3Histiocytoma, Malignant Fibrous 3Colorectal Neoplasms 3Chordoma 3Carcinoma, Neuroendocrine 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Brain Neoplasms 3Urogenital Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2

Interventions

pembrolizumab 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Small Cell × Ipilimumab × Clear all
NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡